Compare Anheuser-Busch Inbev SA (BUD) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Cronos Group Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.27 (market cap $159.01B), while Cronos Group Inc trades at $3.13 (market cap $1.14B). The key difference: Anheuser-Busch Inbev SA is far larger — about 139.5× Cronos Group Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| BUD | CRON | |
|---|---|---|
Market Cap | $159.01B | $1.14B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $3.27 |
52-Week Low | $57.93 | $2.30 |
Enterprise Value | $223.42B | $341.13M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.
The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.
Cronos Group (CRON) trades at $3.125, up 4.17% today. The stock shows a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with $0.09 EPS versus $0.01 expected, driven by 58% YoY revenue growth. However, the company posted a net loss of $9.45M in 2025, though margins are improving from prior years.
Outlook is mixed; strong international expansion and product launches support growth, but negative cash flow and intense competition pose risks. Analyst consensus is cautious with 60% hold ratings. The stock offers growth potential but requires monitoring of profitability and cash management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
